- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01906502
24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population
August 25, 2014 updated by: Sensimed AG
A Prospective, Open Label Study to Assess the 24-hour IOP Pattern Recorded With SENSIMED Triggerfish® in a Healthy Population
A database (Snapfish) has been generated at Sensimed compiling all data acquired up to now on healthy volunteers and patients with glaucoma.
However, healthy subjects were much younger than glaucoma patients.
Additionally, the number of glaucoma patients in Snapfish database was almost twice higher than the number of healthy subjects.
As it is generally accepted that intra ocular pressure (IOP) in the aging population is higher than IOP in young adults it is of interest to evaluate the 24-hour IOP pattern of older healthy subjects.
Furthermore, improving our knowledge of the "healthy" 24-hour IOP pattern in comparison to glaucoma profiles would be beneficial for management of glaucoma.
Study Overview
Study Type
Interventional
Enrollment (Actual)
115
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kfar Saba, Israel
- Meir Medical Center
-
Naharya, Israel
- The Western Galilee Hospital in Naharya
-
Petach Tikva, Israel
- Rabin Medical Center
-
Rehovot, Israel
- Kaplan Medical Center
-
Tel Aviv, Israel
- Sourasky Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject of Caucasian origin
- Healthy subject without previous ocular disease
- Aged between 40 and 80 years, of either sex
- Not more than 6 diopters spherical equivalent in the study eye
- Having given written informed consent, prior to any investigational procedures
Exclusion Criteria:
- Corneal or conjunctival abnormality precluding contact lens adaptation
- Previous refractive surgery
- Occludable or closed iridocorneal angle
- Sleep apnea syndrome
- Subjects with allergy to corneal anesthetic
- Subjects with contraindications for silicone contact lens wear
- Subjects not able to understand the character and individual consequences of the investigation
- Participation in other clinical research within the last 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Device
Portable device that monitors the 24-hour IOP pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals via an antenna around the orbital cavity to a recorder.
Upon completion, the recording can be transmitted to a computer for read-out and visualization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The 24-hour IOP pattern recorded with Sensimed Triggerfish (TF) in healthy subjects, aged between 40 and 80 years Secondary
Time Frame: 24-hour
|
24-hour
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Diurnal and nocturnal IOP patterns in healthy subjects
Time Frame: 24 hours
|
24 hours
|
|
Assessment of corneal biomechanical properties in healthy population (if available)
Time Frame: 24 hours
|
24 hours
|
|
Relationship between the 24-hour IOP pattern monitored by TF and the 24-hour blood pressure pattern in healthy subjects (if available)
Time Frame: 24 hours
|
24 hours
|
|
Assessment of Safety and tolerability through adverse events
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: moshe lusky, MD, Rabin Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2013
Primary Completion (ACTUAL)
April 1, 2014
Study Completion (ACTUAL)
April 1, 2014
Study Registration Dates
First Submitted
July 17, 2013
First Submitted That Met QC Criteria
July 20, 2013
First Posted (ESTIMATE)
July 24, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
August 26, 2014
Last Update Submitted That Met QC Criteria
August 25, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Other Study ID Numbers
- TF-1217
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subject
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Changchun GeneScience Pharmaceutical Co., Ltd.Completed
-
CelltrionCompletedHealthy SubjectKorea, Republic of
-
Staidson (Beijing) Biopharmaceuticals Co., LtdCompleted
-
GeneScience Pharmaceuticals Co., Ltd.Completed
-
Kyowa Kirin Co., Ltd.Completed
-
University Hospital, LilleTerminatedHealthy SubjectFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...Active, not recruitingHealthy SubjectUnited States
-
Hospices Civils de LyonCompleted
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingHealthy SubjectUnited States
Clinical Trials on Sensimed Triggerfish
-
Sensimed AGUniversity Hospital, GenevaTerminated
-
Sensimed AGPrivate practicioner, Dr Sunaric Mégevand; Orasis, AugenZentrum PajicTerminatedPigmentary Dispersion Syndrome | Pigmentary Glaucoma PatientsSwitzerland
-
Sensimed AGCompleted
-
Sensimed AGTerminatedPrimary Open-angle Glaucoma (POAG) PatientUnited States
-
Sensimed AGCompletedSleep Apnea, Obstructive | Primary Open-angle GlaucomaUnited States
-
Sensimed AGClinique MonchoisiTerminatedPrimary Open Angle GlaucomaSwitzerland
-
Sensimed AGCompleted
-
University Hospital, BordeauxCompletedOpen Angle Glaucoma With a Progressive Visual FieldFrance